To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
Researchers at CEA-Joliot (SPI unit in collaboration with SIMoS unit) have developed a monoclonal antibody directed against a common region of two proteins of the bacteria Shigella and Salmonella and capable of inducing cross-protection against infections caused by these bacteria.
By studying the structure-reactivity relationships of bio-inspired catalysts for CO2 reduction, researchers from I2BC (SB2SM) and ICMMO have shown that the effects of through-space electrostatic interactions surpass the through-bonds electronic effects. A further step towards obtaining a durable catalyst to reduce the atmospheric accumulation of CO2, responsible for global warming.
I2BC researchers, in collaboration with the European Institute of Chemistry and Biology (University of Bordeaux, CNRS), have developed a chimeric peptide/foldamer molecule that is resistant to proteolysis and inhibits ASF1, a potential target for anticancer treatment. The resolution of the structure of this chimera in interaction with its target, the first of its kind, reveals an unsuspected plasticity of the urea-based backbone that hugs the surface of ASF1.
SPI (DMTS), in collaboration with ANSES, has developed a test based on immuno-capture and targeted mass spectrometry for the quantitative and multiplex identification, in dairy products, of the eight main enterotoxins of Staphylococcus aureus, responsible for food poisoning epidemics.
I2BC researchers, in collaboration with the Autonomous University of Barcelona, have provided the first studies of the function and structural organization of a flippase encoded by a parasite responsible for malaria, a first step towards understanding the essential physiological function of this transporter and its potential use as an antimalarial target.
Le LEMM, en collaboration avec le LI2D et l’AP-HP, développe un test de diagnostic spécifique de la Covid-19 par spectrométrie de masse qui permettrait aussi la quantification de la charge virale du patient. Objectif à terme : adapter la méthode pour la rendre plus sensible et compatible avec les équipements d’analyse des hôpitaux.
By combining molecular dynamics and in vitro experiments, researchers at the LPSM (I2BC) have revealed the mode of action of sarcolipin in regulating the activity of SERCA1a, responsible for muscle relaxation.
A SCBM (DMTS) team, in collaboration with researchers at NeuroSpin and I2BC, is describing micellar nanometric vectors targeting tumors that have been imaged by fluorine magnetic resonance imaging (MRI). The observed 19F signal made it possible to precisely delimit the volume of the tumor zone in a mouse model and to quantify the probe accumulated in the target tissue.
Researchers from the LMC (DMTS), in collaboration with a team from AstraZeneca, have developed a labeling method, based on the exchange of carbon dioxide, simply using visible blue light and a photocatalyst.
The TIRO team (SHFJ), in collaboration with the neurovascular clinicians of the Nice and Marseille University Hospitals, carried out analyses of the metabolome of cerebral clots at the origin of the occlusion of a cerebral artery responsible for a cerebral vascular accident (stroke). A pilot study that improved the understanding of the complex relationship between blood glucose levels and patients' functional prognosis.
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.